Report

BRAIN AG : Upgrade to Buy, but TP cut to € 18 (from € 23)

>Upgrade to Buy as the share is oversold - BRAIN’s share price has declined massively since August driven, as we understand, by i/ the lack of newsflow on the biologic sweetener, ii/ management’s impaired credibility due to the delayed launch of the salt taste enhancer, exacerbated by iii/ the departure of CFO Frank Göbel in August after just 1.5 years with the company, and iv/ the overall sell-off. In our view, however, the current share price more than reflects al...
Underlying
Brain Biotechnology Research and Information Network AG

BRAIN Biotechnology Research and Information Network AG is a Germany-based industrial biotechnology company, which is active in two segments: The BioSciences segment comprises research and development activities related to replacing classical chemical and industrial processes with biotechnology processes, and the BioIndustrial segment focuses on the development of own products for both companies and consumers. The Company develops drugs, bioactive natural compounds and enzymes for customers in the chemical and pharmaceutical industries, as well as in the food and cosmetics industries. It offers research and development collaboration, as well as strategic partnerships and exclusive licensing agreements through all phases of enzyme and biological compound discovery to application development and production. The Company's product portfolio includes EvoSolution, METAGENOME, BRAINzyme, LIL, ABEL, CompActives and BioCompActives.

Provider
Oddo BHF
Oddo BHF

​Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

Other Reports on these Companies
Other Reports from Oddo BHF

ResearchPool Subscriptions

Get the most out of your insights

Get in touch